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Introduction: Detyrosinated tubulin, a post-translational modification of α-tubulin and a hallmark of stable
microtubules, has gained recent attention given its association with tumor progression, invasiveness, and
chemoresistance. We also recently reported that epithelial-to-mesenchymal transition (EMT) promotes tubulin
detyrosination through tubulin tyrosine ligase (TTL) suppression. Furthermore, detyrosinated tubulin-enriched
membrane protrusions, termed microtentacles (McTN), facilitate tumor cell reattachment to endothelial layers.
Given the induction of EMT associated with inflammation and cancer progression, we tested anti-inflammatory
nuclear factor-kappaB (NF-κB) inhibitors on a panel of human breast carcinoma cells to examine their effects on
detyrosinated tubulin to identify more specific tubulin-directed anti-cancer treatments.
Methods: Using metastatic human breast carcinoma cells MDA-MB-157, MDA-MB-436, and Bt-549, we measured
the impact of NF-κB inhibitors parthenolide, costunolide, and resveratrol on detyrosinated tubulin using protein
expression analysis and immunofluorescence. A luciferase reporter assay and a viability screen were performed to
determine if the effects were associated with their NF-κB inhibitory properties or were a result of apoptosis. Real-
time monitoring of cell-substratum attachment was measured utilizing electrical impedance across microelectronic
sensor arrays. We compared the selectivity of the NF-κB inhibitors to specifically target detyrosinated tubulin with
traditional tubulin-targeted therapeutics, paclitaxel and colchicine, throughout the study.
Results: Sesquiterpene lactones, parthenolide and costunolide, selectively decrease detyrosinated tubulin
independent of their inhibition of NF-κB. Live-cell scoring of suspended cells treated with parthenolide and
costunolide show reduction in the frequency of microtentacles and inhibition of reattachment. Structural analysis
shows that parthenolide and costunolide can decrease detyrosinated microtubules without significantly disrupting
the overall microtubule network or cell viability. Paclitaxel and colchicine display indiscriminate disruption of the
microtubule network.
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Conclusions: Our data demonstrate that selective targeting of detyrosinated tubulin with parthenolide and
costunolide can reduce McTN frequency and inhibit tumor cell reattachment. These actions are independent of
their effects on NF-κB inhibition presenting a novel anti-cancer property and therapeutic opportunity to selectively
target a stable subset of microtubules in circulating tumor cells to reduce metastatic potential with less toxicity in
breast cancer patients.Introduction
Microtubules have long been a target for cancer therapy
given their critical and diverse cellular functions in intra-
cellular transport and metabolism, as well as cell shape,
signaling, migration, polarization and division [1]. Despite
the attractiveness of microtubules as cancer targets, the
clinical effectiveness and tolerance of microtubule-directed
agents are limited, largely due to toxicity, broad and/or un-
determined mechanisms of action, inherent or acquired
resistance and tubulin mutations that reduce drug binding
[2]. Alterations in tubulin-binding sites, microtubule asso-
ciated proteins (MAPs) and microtubule dynamics have
all been implicated as mechanisms for tumorigenesis,
chemoresistance and metastasis [3]. To improve and ad-
vance the therapeutic benefits of microtubule-targeted
compounds for cancer treatment, research has focused on
combination therapy, discovering novel tubulin or tubulin-
associated drug targets and elucidating more specific drug
mechanisms. More importantly, better characterization of
microtubule function, regulation and role in cancer pro-
gression and chemoresistance continue to advance the de-
velopment of clinically-applicable, novel tubulin-directed
chemotherapies.
Microtubules can undergo phases of growth and
shrinkage by modulating dynamic instability; however,
stabilization of a subset of microtubules is necessary for
cell motility [4] and morphogenetic events [5]. Selective
stabilization occurs prior to changes in cell behavior [6],
indicating that stabilization is an early causative event
rather than a result of alterations in cell behavior. These
stable microtubules are enriched in detyrosinated tubu-
lin, a reversible post-translational modification on the
C-terminus of α-tubulin, regulated by the enzymatic ac-
tivity of tubulin tyrosine ligase (TTL) and an ill-defined
tubulin carboxypeptidase (TCP). Detyrosination has
been shown to be a consequence of microtubule stability
and the precise function of this post-translational modi-
fication on microtubule dynamics and regulation is still
unclear. Early insight into microtubule stability suggests
that stable microtubules enriched in detyrosinated tubu-
lin are more resistant to microtubule antagonists [4]. In
addition to its implications for chemoresistance, research
has shown that increased detyrosinated tubulin is associ-
ated with poor cancer prognosis [7] and may arise fromsuppressed TTL activity during tumor growth which pre-
vents re-tyrosination [8,9]. Moreover, TTL−/− cells exhibit
decreased microtubule sensitivity to depolymerizing drugs
as well as microtubule overgrowth and persistence at
the cell’s leading edge [10], potentially contributing to
abnormal cell behavior. We have recently reported that
epithelial-to-mesenchymal transition (EMT) promotes
α-tubulin detyrosination by downregulating expression of
TTL and that detyrosinated tubulin accumulates at inva-
sive tumor fronts in patient samples [11]. Furthermore, we
have shown that microtentacles (McTNs), tubulin-based,
dynamic membrane protrusions that occur at high fre-
quencies in detached metastatic cell lines, are enriched in
detyrosinated tubulin and facilitate tumor cell reattach-
ment and cell-cell adhesion [11,12]. This evidence high-
lights the importance of the tubulin tyrosination cycle in
cancer progression and reveals detyrosinated tubulin as a
novel microtubule target in the metastatic cascade.
The relationship between EMT, inflammation and can-
cer progression has received considerable attention in
the last several years [13]. Given our recent discovery
that EMT promotes detyrosination of α-tubulin in com-
bination with data linking chronic inflammation and
associated nuclear factor-kappaB (NF-κB) activation to
the induction of an EMT [14,15], we decided to test
anti-inflammatory compounds to determine their impact
on tubulin detyrosination and McTN occurrence.
Parthenolide and costunolide, members of the natural
compound sesquiterpene lactone group, have been well-
characterized as inhibitors of the NF-κB pathway and ef-
fective anti-inflammatory drugs but are less recognized
for their microtubule-interfering properties [16,17]. A
recent report, however, uncovered parthenolide’s ability
to inhibit TCP activity to restore functional tyrosinated
tubulin levels and reduce detyrosination [18]. Parthenolide
and costunolide could possibly interfere with microtubules
through their potent NF-κB inhibitory properties. There is
conflicting evidence suggesting that depolymerization of
microtubules can decrease translocation of active NF-κB
into the nucleus or induce NF-κB activity and transactiva-
tion of NF-κB-dependent genes [19,20]. Additionally,
microtubule stabilizers such as Taxol may promote NF-κB
activation [21] or have no effect [20]. Despite the
conflicting data, it is apparent that interfering with
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activity. Therefore, the question remains whether the
ability of parthenolide and costunolide to reduce stable,
detyrosinated tubulin in metastatic breast cancer cells oc-
curs through a mechanism that is dependent or independ-
ent of their NF-κB inhibitory properties.
Our past research has used broad microtubule and
actin disrupting agents as tools to determine the struc-
ture and function of McTNs. These tools have been use-
ful to define McTNs as tubulin-based and distinguish
McTNs from actin-based membrane structures, but have
limited value when translated to the clinic due to their
toxicity and severe disruption of the entire microtubule
array. The primary focus of the current report is to iden-
tify novel therapeutic candidates that move beyond indis-
criminate targeting of microtubules, enabling reductions
in McTNs and the reattachment proficiencies of meta-
static breast cancer cell lines by specifically targeting
detyrosinated tubulin. We also investigate whether the ef-
fects of parthenolide and costunolide on detyrosination
are related to their NF-κB inhibitory activity or if a separ-
ate mechanism is responsible and reveals multi-faceted
targets for these anti-cancer therapies.
Methods
Cell culture and chemical compounds
Bt-549 and MDA-MB-436 were maintained at 37°C in (D)
MEM (Mediatech, Inc., Manassas, VA) in 5% CO2 while
MDA-MB-157 was cultured in L-15 media (Life Technolo-
gies, Carlsbad, CA) at 37°C without CO2. Cells were
obtained by American Type Culture Collection (Manassas,
VA, USA) and growth media was supplemented with 10%
fetal bovine serum (FBS) and penicillin-streptomycin (100
μg/ml). Parthenolide (Parth), resveratrol (ResV), colchicine
(Col), and paclitaxel (Taxol;Tax) were obtained from Sigma
(St. Louis, MO, USA). Costunolide (Cost) was purchased
from Chromadex (Santa Ana, CA, USA). Recombinant hu-
man TNF-α was from PeproTech (Rocky Hill, NJ, USA).
This study did not require approval from an ethics
committee.
Immunoblot
Cells were treated for six hours in growth media using a
concentration range containing vehicle (0.1% dimethyl sulf-
oxide (DMSO)), Parth, Cost, ResV, Col or Tax. Cells were
harvested as previously described [12]. Total protein
(12 μg) was separated by SDS-PAGE on 4% to 12% NuPage
MES Bis-Tris gels (Life Technologies). Membranes were
blocked in 5% milk/Tris-buffered saline - Tween (TBST)
for one hour at room temperature followed by an overnight
incubation at 4°C in polyclonal detyrosinated α-tubulin
(1:1000; abCam, Cambridge, MA) poly (ADP-ribose)
polymerase (PARP; H-250, Santa Cruz Biotechnology;
1:1000), or monoclonal α-tubulin DM1A (1:5000; Sigma)in 2.5% milk/TBST. Secondary antibodies to immuno-
globulin G-horse radish peroxidase (IgG-HRP) were used
(1:10000; Jackson ImmunoResearch, West Grove, PA).
Densitometry was performed using ImageJ.
NF-κB activation
Cells were transduced with NF-κB -luciferase reporter
adenovirus (Ad-NF-κB -Luc; 1 × 106 PFU/ml) obtained
from Vector Biolabs (Philadelphia, PA, USA) for 24 hours.
Cells were then split into a microplate to ensure uniform
cell density. Following four hours of drug treatment, cells
were stimulated with TNF-α (100 ng/ml) for one hour
remaining in the presence of drug. D-Luciferin (Caliper Life
Sciences, Alameda, CA; 200 μg/ml) was added and lumi-
nescence was detected on a Berthold LB 940 Mirthras. All
values are shown as mean ± SD of triplicate samples.
Cell viability
Cells were seeded into 96-well microplates and treated in
triplicate for six hours. CellTiter 96 AQueous One Solution
(Promega, Madison, WI) was followed according to the
manufacturer’s protocol to determine cell viability. Ab-
sorbance was measured using a Biotek Synergy HT
Multidetection Microplate Reader. All values are shown
as mean ± SD of triplicate samples.
Live cell imaging and microtentacle scoring
GFP-membrane targeted AcGFP1-Mem plasmid (Clontech,
Mountain View, CA) was used to generate a custom adeno-
virus (Ad-GFP-Mem; Vector BioLabs) for McTN scoring
and population imaging. Cells were transduced for 24 hours
and then treated with drug for 6 hours prior to detachment.
Detailed methods for live cell imaging and McTN scoring
were previously described [12]. Single Ad-GFP-Mem+cells
were scored blindly for McTNs at 15 to 30 minutes while
suspended in an ultra-low attachment plate (Corning,
Corning, NY) in the respective drug-containing growth
media. Images were collected using an Olympus CKX41
inverted fluorescent microscope (Melville, NY, USA) and
analysis was performed using Olympus MicroSuite Five
software. Cell images were collected following detachment
as grayscale images and subsequently color inverted for
better visualization contrast. The original images were
contrasted equivalently using ImageJ.
Indirect immunofluorescence
Cells were drug treated on glass coverslips for six hours
then fixed in 3.7% formaldehyde/PBS. Fixed cells were
permeabilized (0.25% Triton X-100/PBS, 10 minutes),
and blocked for one hour (PBS/5% bovine serum albu-
min (BSA)/0.5% NP40). Immunostaining was performed
overnight at 4°C (PBS/2% BSA/0.5% NP40) using poly-
clonal detyrosinated α-tubulin (abCam) and monoclonal
α-tubulin DM1A (Sigma). Image acquisition was captured
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scope (Olympus, Center Valley, PA, USA).
Cell-electrode impedance attachment assay
Real-time monitoring of cell-substratum attachment was
measured utilizing the xCELLigence RTCA SP real-time
cell sensing device (ACEA Biosciences, San Diego, CA).
Cells were pretreated for six hours, trypsinized and
counted. Cells (20,000) were seeded into 96-well microelec-
tronic sensored standard plates (E-plates) containing the re-
spective drug. Briefly, attachment is measured from the
interaction of cells with the electrodes and represented as a
change in cell index (CI), an arbitrary unit derived from the
relative change in electrical impedance across microelec-
tronic sensor arrays. The electrical impedance was captured
every three minutes for an experimental duration of 3.5
hours. The attachment rate is expressed as the CI, or the
change in electrical impedance at each timepoint. Values
are expressed as the +/− SD of the triplicate wells. Three
independent trials were conducted.
Results
Parthenolide and costunolide decrease detyrosinated
tubulin in human breast carcinoma cells
Human breast carcinoma cell lines, MDA-MB-157,
Bt-549 and MDA-MB-436 were treated with anti-
inflammatory or microtubule-targeting drugs to deter-
mine their effect on detyrosinated tubulin. These cell
lines were selected based on their metastatic properties
as well as our previous research demonstrating high
McTN frequencies and detyrosination of α-tubulin [12].
Following six hours of treatment, all cell lines show a
significant dose-dependent decrease in detyrosinated
tubulin in the presence of 10 to 25 μM of Parth and
Cost (Figure 1A and B) (Bt-549: Parth10 (P <0.001),
Parth25 (P < .001); Cost5 (P <0.05), Cost10 (P <0.05),
Cost25 (P <0.001)), (MDA-MB-157: Parth10 (P <0.001),
Parth25 (P <0.001); Cost10 (P <0.001), Cost25 (P <0.05)).
The absence of PARP cleavage indicates that this con-
centration range did not reduce detyrosinated tubulin
as a result of apoptosis. Treatment with ResV, a non-
sesquiterpene lactone NF-κB inhibitor (Figure 1A and
B), did not show a significant decrease (MDA-MB-
157 and Bt-549 = P >0.5) in detyrosinated tubulin
suggesting that the effects of Parth and Cost on
detyrosinated tubulin are independent of their NF-κB
inhibitory properties. Traditional microtubule-targeting
drugs were included to show the effect on detyrosinated
tubulin when microtubules are either destabilized (Col)
or stabilized (Tax). The six-hour timepoint was chosen
based on prior reports that have shown that the NF-κB
inhibitory effects of Parth, Cost and ResV are realized
within a three- to eight-hour window [22,23] as well as
a time course of Parth and Cost in the experimental celllines to determine when detyrosinated tubulin was sig-
nificantly reduced [see Additional file 1: Figure S1].
Comparison of the drug structures shows strong simi-
larity between Parth and Cost, which differ only in an
epoxide group, while the other compounds are structur-
ally dissimilar (Figure 1B).
Previous research using a novel high-throughput
cell-based immunoluminescence assay has shown that
Parth, but not Cost, can prevent accumulation of
detyrosinated tubulin purportedly through TCP inhib-
ition following a two hour treatment duration; however,
these experiments were conducted in HeLa cells which
have undetectable levels of detyrosinated microtubules
(13). We report here that both Parth and Cost can
significantly reduce detyrosinated tubulin in multiple
invasive breast carcinomas with abundant detyrosinated
microtubules. Our observation that Cost can reduce
detyrosinated tubulin similarly to Parth may indicate
that breast cancer cell lines with increased detyrosination
levels are more susceptible to inhibition, or that
extending treatment beyond two hours is required to
realize the inhibitory action of Cost [see Additional file
1: Figure S1].
Tubulin detyrosination is independent of the NF-κB
pathway
Since normal cells are not generally as sensitive as tumor
cells to sesquiterpene lactones due to low basal NF-κB
activity, these compounds may target cancers in which
the NF-κB pathway is constitutively activated. Studies
have also shown that NF-κB activity has been associated
with the polymerization state of microtubules. There-
fore, we used an NF-κB reporter assay to determine if
the effects of Parth and Cost on detyrosinated tubulin
are related to their anti-inflammatory properties. Parth
and Cost effectively inhibit TNF-α-induced NF-κB
activation (Figure 2A, Additional file 2: Figure S2A) at
the concentrations that reduce detyrosinated tubulin
(Figure 1A). ResV also inhibited NF-κB (Figure 2A,
Additional file 2: Figure S2A) but did not affect
detyrosinated tubulin (Figure 1A), highlighting that the re-
duction in detyrosinated tubulin is independent of NF-κB
inhibition. Tax increased detyrosinated tubulin but did
not inhibit or synergistically increase TNF-α activation
of NF-κB in all cell lines. Interestingly, Col decreased
detyrosinated tubulin but caused a moderate increase in
the NF-κB activation in all lines, suggesting that micro-
tubule depolymerization may activate NF-κB as previ-
ously reported. Furthermore, the drug concentrations
used did not affect viability (Figure 2B, Additional file
2: Figure S2B). These results indicate that the effects
on detyrosinated tubulin are independent of NF-κB acti-
vation, revealing novel anticancer properties of these two
sesquiterpene lactones.
Figure 1 Parthenolide and costunolide decrease detyrosinated tubulin in human breast carcinoma cells. (A) Bt‐549 (N = 3) and MDA‐MB‐
157 (N = 6) cells treated for six hours with DMSO (Veh; 0.1%), parthenolide (Parth; 5 μM, 10 μM, 25 μM), costunolide (Cost; 5 μM, 10 μM, 25 μM),
resveratrol (ResV; 50 μg/ml), colchicine (Col; 50 μM), and Taxol (Tax; 0.5 μg/ml). Parthenolide (10 μM, 25 μM), costunolide (10 μM, 25 μM), and
colchicine (50 μM) significantly reduced detyrosinated tubulin (Detyr) levels compared to vehicle (*P <0.05; ** P <0.001, t‐test). Resveratrol, a non‐
sesquiterpene lactone NF‐κB inhibitor, did not significantly affect detyrosinated tubulin (P >0.5, t‐test). Taxol significantly increased detyrosinated
tubulin (‡Bt‐549 Tax value is × 2.5; MDA‐MB‐157 Tax value is × 10). None of the compounds induced apoptosis in these cells, as gauged by PARP
cleavage. Columns, mean densitometry for N = 3 (Bt‐549) or N = 6 (MDA‐MB‐157) experiments; bars, SD. (B) Comparison of the compounds used
show parthenolide and costunolide, two sesquiterpene lactones, are structurally similar while the other compounds are structurally dissimilar.
DMSO, dimethyl sulfoxide; NF-κB, nuclear factor-kappaB; PARP, poly(ADP-ribose) polymerase.
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tubulin without compromising the overall microtubule
network
While detyrosinated microtubules have been implicated
in tumor aggressiveness, exclusive targeting of this post-
translational modification with effective small molecule
compounds has been a greater challenge. The majority
of current anti-tubulin agents bind directly to tubulin
and affect microtubule dynamics, ultimately impairing
cellular functions to an extent that inhibits proliferation
and triggers apoptosis. While this is the desired outcome
for cancer cells, the side effects can lead to toxicity in
non-target cells resulting in clinical limitations. There-
fore, immunofluorescence was performed to investigatethe structural impact of Parth and Cost on detyrosinated
microtubules relative to the overall microtubule net-
work. The vehicle treatment (0.1% DMSO) did not affect
the elaborate filamentous detyrosinated tubulin that was
observed in nearly every cell in the population (Figure 3A
and B). ResV did not affect either detyrosinated tubulin
or the microtubule network. The microtubule destabiliz-
ing drug Col significantly disrupted the detyrosinated
microtubules while also destroying the overall micro-
tubule array. Tax increased cellular levels and bundling,
and altered the organization of detyrosinated microtu-
bules while also affecting the microtubule network. Tax
also caused cell shrinkage in both lines. Interestingly,
Parth and Cost decreased detyrosinated microtubules
Figure 2 Tubulin detyrosination is independent of NF-κB activation. (A) NF-κB -luciferase reporter adenovirus infected MDA-MB-157 and
Bt-549 show that a four-hour treatment of parthenolide (Parth; 10 μM, 25 μM) and costunolide (Cost; 10 μM, 25 μM) inhibit TNF-α-induced
(100 ng/ml) NF-κB activation at concentrations that reduced detyrosinated tubulin. Resveratrol (ResV; 50 μg/ml, 100 μg/ml) inhibits NF-κB but
does not affect detyrosination. Colchicine (Col; 50 μM) and Taxol (Tax; 0.5 μg/ml) do not inhibit NF-κB at concentrations that affect detyrosinated
tubulin. (B) Cell viability assay shows that non-toxic drug concentrations are used. All compounds are expressed as a % of vehicle (set at
100%; horizontal dotted line). NF-κB, nuclear factor-kappaB.
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demonstrating that these compounds have more
targeted effects on stabilized microtubules than either
Col or Tax. These results, in combination with the west-
ern blot, show that Parth and Cost selectively decrease
detyrosinated microtubules.
Parthenolide and costunolide decrease microtentacle
(McTN) frequency
Our previous research has identified detyrosinated α-
tubulin as a structural component of McTNs observed
in detached cells. Additionally, increased McTN fre-
quency has been correlated with invasiveness in a panel
of breast tumor cell lines [12]. Based on Parth and Cost’s
ability to selectively reduce detyrosinated tubulin, we in-
vestigated their effects on McTN frequency using a
panel of invasive human breast carcinoma cells with
high McTN frequency. Following six hours of treatment,cells infected with a membrane-targeted GFP were
detached in drug-containing media and McTNs were
scored blindly. Parth and Cost significantly (all lines:
P <0.001) reduced McTN frequency to a greater extent
than Col (Figure 4A; Additional file 3: Figure S3A). ResV
and Tax did not change McTN frequency compared to
the vehicle control (Figure 4A and B, Additional file 3:
Figure S3A and B). Live-cell imaging of the detached
population illustrates the considerable reduction in
McTNs in the presence of Parth and Cost (Figure 4B,
Additional file 3: Figure S3B).
Parthenolide and costunolide reduce tumor cell
attachment
We previously showed that McTNs facilitate cell attach-
ment to ECM and to an endothelial layer [11]. Addition-
ally, mesenchymal cells with increased detyrosinated
tubulin and McTNs attach at a faster rate than their
Figure 3 Parthenolide and costunolide decrease detyrosinated tubulin without compromising the overall microtubule network.
Immunofluorescence of six-hour drug treated (A) Bt-549 and (B) MDA-MB-157 stained for detyrosinated tubulin and α-tubulin show that
parthenolide (Parth; 10 μM) and costunolide (Cost; 25 μM) decrease and disrupt filamentous detyrosinated tubulin (Detyr) while leaving the
overall microtubule network intact (α-tub). Treatment with colchicine (Col; 50 μM) disrupts both detyrosinated and α-tubulin filaments. Taxol (Tax;
0.5 μg/ml) increases bundling and disrupts organization of detyrosinated and α-tubulin filaments. Resveratrol (ResV; 50 μg/ml) did not significantly
affect detyrosinated or α-tubulin.
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tions in McTN frequencies and selective targeting of
detyrosinated tubulin by Parth and Cost, we compared
the reattachment efficiency of each line in the presence
of drug using real-time electrical impedance monitoring.
Each cell line was pretreated for six hours and then
plated into media containing the respective drug in spe-
cialized E-plates with sensor electrode arrays. Real-time
attachment monitoring shows that Parth and Cost
inhibited cells from reattaching in all lines while ResV and
Tax attached similarly to the vehicle control (Figure 5;
Additional file 4: Figure S4 and Additional file 5: Figure
S5). Interestingly, Col treatment decreased attachment in
Bt-549 and MDA-MB-436 more strongly than in MDA-
MB-157, illustrating differences in cell sensitivity. These
results suggest that Parth and Cost reduced attachment by
affecting detyrosinated tubulin, a major structural compo-
nent of McTNs.Discussion
Metastasis causes 90% of deaths from solid tumors;
therefore, novel chemotherapeutic strategies that go be-
yond primary tumor treatment and inhibit metastatic
dissemination are critical. Since cancer cells can be shed
from primary tumors that remain below the threshold of
detection [24] and microtubules can influence the meta-
static cascade, the effects of microtubule-directed com-
pounds on circulating tumor cells are a crucial area for
investigation. Interestingly, treatment with a tubulin de-
polymerizing agent prevents circulating colon carcinoma
cells from attaching to the microvascular endothelium
in vivo, highlighting a microtubule-dependent mechan-
ism for circulating tumor cell retention in distant tissues
[25]. Recent patient studies have further shown a rapid
increase of circulating tumor cells in the bloodstream
with neoadjuvant taxane treatment and a two-fold
higher frequency of relapse compared to adjuvant taxane
Figure 4 Parthenolide and costunolide decrease microtentacle (McTN) frequency and attachment. (A) Detached Bt-549 and MDA-MB-157
were pretreated for six hours and suspended in drug-containing media for blind McTN scoring. Parthenolide (Parth; 10 μM), costunolide (Cost; 25
μM), and colchicine (Col; 50 μM) show a significant decrease compared to vehicle treated (*P <0.05; ** P <0.001, t-test). Resveratrol (ResV; 50 μg/
ml) and Taxol (Tax; 0.5 μg/ml) did not have a significant effect on McTN frequency. Columns, mean %McTNs for six independent experiments in
which at least 100 cells were scored blindly; bars, SD. (B) Live population images of suspended Bt-549 and MDA-MB-157. McTNs are observed in
vehicle, resveratrol, and Taxol (black arrows).
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trations have been correlated with increased survival in
some tumor cells compared to lower doses [26]. Re-
search from our laboratory has identified tubulin-basedMcTNs in detached cells that facilitate reattachment
to endothelial layers, a tubulin-driven mechanism that
possibly connects the data observed in vivo and in pa-
tients treated with microtubule stabilizers. These data
Figure 5 Parthenolide and costunolide reduce reattachment efficiency of human breast carcinoma cells. Real-time electrical impedance
monitoring shows that parthenolide (10 μM) and costunolide (25 μM) significantly reduce attachment when compared to vehicle while Taxol
(0.5 μg/ml) and resveratrol (50 μg/ml) did not. Colchicine (50 μM) reduced attachment to a greater extent in Bt-549 than in MDA-MB-157.
Lines, mean for three triplicate wells; bars, SD; representative graph is shown. Three independent experiments were performed [see Additional
file 4: Figure S4].
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selecting the most appropriate patient treatment when
circulating tumor cells are present.
Our present results show that Parth and Cost can re-
duce McTNs by specifically targeting detyrosinated tubu-
lin unlike traditional tubulin-targeted compounds, Tax
and Col. These observations support previous evidence
showing that Tax alone is insufficient to stimulate the for-
mation of new McTNs in invasive cell lines but can
stabilize existing structures to promote MT-dependent ad-
hesion and cell spreading [27]. Interestingly, conditions
where filamentous actin is disrupted within the cell show
a robust increase in stable microtubules [28] and McTN
frequency when treated with Tax [27], highlighting the
consequences when the microtubule-microfilament
interaction is unbalanced and stable microtubules are
unrestricted. This evidence is of particular relevance
given data showing that EMT destabilizes cortical actin
[29] and that malignant cells have a 40% reduction in
filamentous actin [30]. Furthermore, microtubules can
continue to grow after membrane contact, divert along
the plasma membrane, push the membrane outward,
and even grow inward in TTL knockout cells [10], con-
ditions that increase detyrosinated tubulin and promote
invasiveness. Therefore, the effects of indiscriminate
disruption of major cytoskeletal networks may contrib-
ute to metastasis or toxic side effects.
Chronic tissue damage and inflammation have been
associated with tumor development as well as EMT
[13,31,32], conditions that may promote persistent
microtubule stability and aberrant detyrosinated tubulin
elevation. Persistent stimuli that activate inflammatory
pathways and elicit a microtubule stabilization responsemay provide selective pressure for mutations that sup-
press TTL activity and/or upregulate the TCP. Interest-
ingly, suppression of TTL has been associated with poor
prognosis in several cancers [7-9]. Due to the limited
characterization of the TCP or resources to measure its
expression, it is unclear what alterations in the TCP
might exist in cancer cells to increase microtubule sta-
bility and possibly provide the cell a selective advantage.
Only recently has AGLB2 been identified as the TCP
that regulates the tubulin tyrosination cycle by interacting
with retinoic acid receptor responder 1 (RARRES1), a
carboxypeptidase inhibitor that is suppressed in aggressive
prostate and breast cancer cells with a mesenchymal
phenotype [33]. Nevertheless, research has shown that
detyrosinated microtubules are oriented towards a wound
site [4] in addition to being upregulated at the tumor
invasive front [11]. This increase in tubulin detyrosination
supports cell migration, proliferation and EMT, likely in-
fluencing metastatic success and chemoresistance. Once
detached and disseminated from the primary tumor, a cir-
culating tumor cell can reattach at a distant site, a process
proposed to be microtubule-driven [25,34]. Therefore,
compounds that can reduce detyrosinated tubulin as well
as inflammation could be a multi-pronged approach for
cancer treatment as well as prevention.
There is growing evidence that select nonsteroidal
anti-inflammatory drugs (NSAID) have anti-cancer
properties, although the mechanisms are still being elu-
cidated [35]. We show that the NSAIDs Parth, Cost and
ResV can inhibit TNF-α activation of NF-κB; however,
only Parth and Cost can selectively reduce detyrosinated
tubulin highlighting that NF-κB inhibition is independ-
ent of effects on tubulin detyrosination. Parth and Cost
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responsible for tubulin detyrosination [18] and reduce
McTNs without total microtubule disruption. Modulat-
ing microtubule stability with alternative chemothera-
peutics may also enable the benefits of Tax treatment to
be realized with combination therapy [36]. Supporting
data indicate that Parth has displayed a significantly bet-
ter prognosis in combination therapy with paclitaxel
than paclitaxel alone in vivo using human gastric cancer
cells as well as breast cancer cells [37,38]. The combin-
ation treatment with Parth in vitro using non-small cell
lung cancer lowered the effective Tax dose required to
induce cytotoxicity [39] as well as resensitized Tax-
resistant cells [40]. Moreover, NSAID sesquiterpene lac-
tones in cancer clinical trials, including Parth, have
displayed selectivity to target tumor and cancer stem
cells while sparing normal cells [38]. Of particular rele-
vance is Parth’s ability to suppress the formation of dis-
seminated nodules in vivo (gastric cancer) and inhibit
bone metastasis of W256 breast cancer cells in mice
[41]. Cost has also shown antiproliferative activity in
leukemia cells as well as efficacy in drug resistant lines
[42] but has been studied to a lesser extent than Parth.
Given detyrosinated tubulin’s role in cell migration and
reattachment, it is possible that Parth’s ability to reduce
detyrosinated tubulin and McTN formation is a contrib-
uting factor to the inhibition of metastasis, a mechanism
that is independent from its anti-inflammatory effects.
Most clinical microtubule-targeted drugs bind directly
to tubulin, resulting in an increase or decrease in the
microtubule mass [43]. It has been noted that tubulin
binding and subsequent dynamic suppression contribute
to the benefits but also to the toxic side effects of these
drugs [2]. Intact microtubule arrays are necessary for
normal cell functions, so it is expected that disrupting
the microtubule network will have significant effects on
both cancer and normal cells. For example, it has been
reported that Col has such high toxicity to normal tis-
sues that its development as an anticancer therapeutic
has been unsuccessful [2]. Encouragingly, it has been
previously shown that it is possible to interfere with
microtubule dynamics without dismantling the entire
microtubule array in order to successfully reduce mi-
gration [44]. Our data show that both Col and Tax se-
verely affect the microtubule network while Parth and
Cost selectively reduce a subset of detyrosinated, stable
microtubules that are associated with tumor aggressive-
ness and EMT. The therapeutic goal is to reduce the
broad toxicity associated with many of the microtubule
chemotherapeutics and direct the treatment at malig-
nant cell hallmarks. Therefore, the enzymes regulating
the detyrosination/tyrosination cycle could be an ap-
pealing and more specific drug target to moderate
microtubule stability in tumors with high levels ofdetyrosinated tubulin rather than broadly targeting
tubulin polymerization with compounds that bind
tubulin subunits directly.Conclusions
Based on the developing evidence, we propose that circulat-
ing tumor cell reattachment is facilitated by detyrosinated
tubulin enriched McTNs [25,34]. Detyrosinated tubulin
may favor aberrant microtubule stability associated with
cell migration [4], proliferation [45], chemoresistance [4],
EMT [11], McTN formation [12], reattachment [11,25]
and tumor aggressiveness [7]. Our data demonstrate that
targeting detyrosinated tubulin with compounds such as
Parth and Cost can reduce McTN frequency and inhibit
reattachment without significantly disrupting the overall
microtubule network or cell viability. These actions are in-
dependent of their effects on NF-κB inhibition presenting
a novel property to these sesquiterpene lactones and an
opportunity to move beyond simply targeting tumor cell
growth. Our results highlight Parth and Cost as potential
compounds to target detyrosinated tubulin more select-
ively. Since this α-tubulin modification promotes McTNs
and tumor cell reattachment, such treatment could reduce
tumor aggressiveness and decrease the risk of recurrence
with less toxicity in breast cancer patients.Additional files
Additional file 1: Figure S1. Bt-549 and MDA-MB-157 cells treated for
one hour, three hours and six hours with parthenolide (Parth; 10 μM),
and costunolide (Cost; 25 μM) show that detyrosinated tubulin is
significantly reduced by six hours compared to DMSO (Veh; 0.1%) treated
cells (N = 3).
Additional file 2: Figure S2. (A) NF-κB -luciferase reporter adenovirus
infected MDA-MB-436 shows that a four hour treatment of parthenolide
(Parth; 10 μM, 25 μM) and costunolide (Cost; 10 μM, 25 μM) inhibits TNF-
α-induced (100 ng/ml) NF-κB activation at concentrations that reduced
detyrosinated tubulin. Resveratrol (ResV; 50 μg/ml, 100 μg/ml) inhibits NF-
κB but does not affect detyrosination. Colchicine (Col; 50 μM) and Taxol
(Tax; 0.5 μg/ml) do not inhibit NF-κB at concentrations that affect
detyrosinated tubulin. (B) Cell viability assay shows that non-toxic drug
concentrations are used. All compounds are expressed as a % of vehicle
(set at 100%; horizontal dotted line).
Additional file 3: Figure S3. (A) Detached MDA-MB-436 were
pretreated for six hours and suspended in drug containing media for
blind McTN scoring. Parthenolide (Parth; 10 μM), costunolide (Cost; 25
μM), and colchicine (Col; 50 μM) show a significant decrease compared
to vehicle treated (*P <0.05; ** P <0.001, t-test). Resveratrol (ResV; 50 μg/
ml) and Taxol (Tax; 0.5 μg/ml) did not have a significant effect on McTN
frequency. Columns, mean %McTNs for four independent experiments in
which at least 100 cells were scored blindly; bars, SD. (B) Live population
images of suspended MDA-MB-436. McTNs are observed in vehicle,
resveratrol, and Taxol (black arrows).
Additional file 4: Figure S4. Real-time electrical impedance monitoring
of MDA-MB-436 shows that parthenolide (10 μM) and costunolide (25
μM) significantly reduce attachment when compared to vehicle while
Taxol (0.5 μg/ml) and resveratrol (50 μg/ml) did not. Colchicine (50 μM)
also reduced attachment. Lines, mean for three triplicate wells; bars, SD;
representative graph is shown.
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http://breast-cancer-research.com/content/15/5/R83Additional file 5: Figure S5. Additional real-time electrical impedance
monitoring experiment trials of Bt-549 and MDA-MB-157 showing that
parthenolide (10 μM) and costunolide (25 μM) significantly reduce
attachment when compared to vehicle while Taxol (0.5 μg/ml) and
resveratrol (50 μg/ml) did not. Colchicine (50 μM) reduced attachment to
a greater extent in Bt-549 than in MDA-MB-157. Lines, mean for three
triplicate wells; bars, SD.
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